Azenosertib for recurrent uterine serous cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing an oral drug called azenosertib for a type of uterine cancer that has come back or spread. It aims to see if blocking a DNA repair pathway can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of uterine cancer called uterine serous carcinoma (or a cancer with a serous part).
- You have already had one round of platinum-based chemotherapy (like carboplatin or cisplatin).
- If your tumor has a high MSI or MMR deficiency, you must have tried a PD-1/PD-L1 immune checkpoint inhibitor, or be unable to take one.
- You are 18 years or older, and your overall health (ECOG score) is 0, 1, or 2 (able to do light activities or be up and about).
- You are willing to have a biopsy before and during treatment, if you have a safe tumor that can be biopsied.
- You have not taken a cell cycle checkpoint inhibitor (like Wee1 or ATR inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial tests afatinib, a targeted pill, in people whose uterine serous cancer has a specific HER2 (HER2/neu) tumor marker. It aims to shrink tumors or control the cancer when it keeps coming back.
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Hear when a new Uterine Serous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.